

January 14, 1971

Dr. William Tabor
A. H. Robins Co.
Richmond, Virginia

Dear Bill,

I am enclosing the statement of investigator form, curriculum vitae, and a signed copy of the protocol for the butaperazine concentrate study. I believe we can fulfil the study goals with the following amendments:

We are not acquainted with the NOSIE. We can try to use this form, if necessary, but would prefer to define the drug related changes in the BPRS and the CGI.

The protocol suggests all patients receive ~~the~~ tablets first and the concentrate on an immediate crossover. We should have a comparison group and will elect to start some patients on the concentrate with a crossover to the tablets.

I estimate an average dose of 50 mg butaperazine daily. For 15 patients, we will require 40 grams butaperazine in tablet form and an equal amount (4 liters) of the concentrate.

We can begin some patients as soon as the supplies are made available, and will complete the study at the optimal center available this spring.

My best regards.

Sincerely yours,

Max Fink, M.D.